tradingkey.logo
tradingkey.logo
Buscar

Zymeworks Inc

ZYME
Añadir a la lista de seguimiento
26.240USD
-0.230-0.87%
Cierre 11-13 16:00(ET)
1.85BCap. mercado
PérdidaP/E TTM

Acerca de Zymeworks Inc Compañía

Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Perfil de Zymeworks Inc

Símbolo de cotizaciónZYME
Nombre de la empresaZymeworks Inc
Fecha de salida a bolsaJun 24, 2019
Director ejecutivoGalbraith (Kenneth H)
Número de empleados280
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 24
Dirección108 Patriot Drive, Suite A
CiudadMIDDLETOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19709
Teléfono13022748744
Sitio Webhttps://www.zymeworks.com/
Símbolo de cotizaciónZYME
Fecha de salida a bolsaJun 24, 2019
Director ejecutivoGalbraith (Kenneth H)

Ejecutivos de Zymeworks Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark Hollywood
Mr. Mark Hollywood
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
133.85K
+0.70%
Mr. Gregory A. (Greg) Ciongoli
Mr. Gregory A. (Greg) Ciongoli
Independent Director
Independent Director
--
--
Ms. Suzanne Monahan
Ms. Suzanne Monahan
Senior Vice President, General Manager - Theravance Biopharma
Senior Vice President, General Manager - Theravance Biopharma
--
--
Ms. Kristin Stafford
Ms. Kristin Stafford
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Lindsey Foulkes
Dr. Lindsey Foulkes
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
--
--
Ms. Bijal Desai
Ms. Bijal Desai
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Ms. Laura O'Connor
Ms. Laura O'Connor
Senior Vice President, Chief Human Resources Officer
Senior Vice President, Chief Human Resources Officer
--
--
Dr. Sabeen Mekan
Dr. Sabeen Mekan
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
--
--
Mr. Brian N. Cherry
Mr. Brian N. Cherry
Director
Director
--
--
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark Hollywood
Mr. Mark Hollywood
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
133.85K
+0.70%
Mr. Gregory A. (Greg) Ciongoli
Mr. Gregory A. (Greg) Ciongoli
Independent Director
Independent Director
--
--
Ms. Suzanne Monahan
Ms. Suzanne Monahan
Senior Vice President, General Manager - Theravance Biopharma
Senior Vice President, General Manager - Theravance Biopharma
--
--
Ms. Kristin Stafford
Ms. Kristin Stafford
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Lindsey Foulkes
Dr. Lindsey Foulkes
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
--
--
Ms. Bijal Desai
Ms. Bijal Desai
Senior Vice President - Finance
Senior Vice President - Finance
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Zymeworks Inc?

Los cinco principales accionistas de Zymeworks Inc son: Mr. Mark Hollywood
tradingkey.logo
Advertencia de Riesgo: Nuestro sitio web y aplicación móvil solo proporcionan información general sobre ciertos productos de inversión. Finsights no proporciona, y la provisión de dicha información no debe interpretarse como que Finsights proporciona, asesoramiento financiero o recomendación para cualquier producto de inversión.
Los productos de inversión están sujetos a riesgos de inversión significativos, incluida la posible pérdida del monto principal invertido y pueden no ser adecuados para todos. El rendimiento pasado de los productos de inversión no es indicativo de su rendimiento futuro.
Finsights puede permitir que anunciantes o afiliados de terceros coloquen o entreguen anuncios en nuestro sitio web o aplicación móvil o en cualquier parte de los mismos y puede ser compensado por ellos en función de su interacción con los anuncios.
© Derechos de autor: FINSIGHTS MEDIA PTE. LTD. Todos los derechos reservados.